Taken together, these advancements could contribute to better patient compliance and higher arrhythmia detection rates." Figure 1 - Zio monitor LTCM patch ECG device by iRhythm Technologies About the "Performance of a Novel Next-Generation Ambulatory ECG Long-Term Patch Monitor: A Multicenter Post-Market Evaluation" study Authors: Bradley P. Knight, Vladimir Fokin, Jeffrey Ellis, Oussama M.Wazni, Rod S. Passman, Mintu P. Turakhia, Suneet Mittal Researchers retrospectively compared U.S. real-world data from patients using two long term continuous monitors monitoring (LTCM) services, iRhythm's prior generation Zio XT service and its next-generation Zio monitor service, both available for commercial use. The analysis period corresponded to the initial launch of Zio monitor and included 14-day prescriptions between May 2022 and September 2023, comprising 7,433 Zio monitors and 1,336,391 Zio XT devices.